181 related articles for article (PubMed ID: 35179782)
1. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Johansson A; Yu NY; Iftimi A; Tobin NP; van 't Veer L; Nordenskjöld B; Benz CC; Fornander T; Perez-Tenorio G; Stål O; Esserman LJ; Yau C; Lindström LS
Int J Cancer; 2022 Jun; 150(12):2072-2082. PubMed ID: 35179782
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
3. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
Creighton CJ; Fu X; Hennessy BT; Casa AJ; Zhang Y; Gonzalez-Angulo AM; Lluch A; Gray JW; Brown PH; Hilsenbeck SG; Osborne CK; Mills GB; Lee AV; Schiff R
Breast Cancer Res; 2010; 12(3):R40. PubMed ID: 20569503
[TBL] [Abstract][Full Text] [Related]
4. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
5. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
6. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiles of progesterone receptor loss in human breast tumors.
Creighton CJ; Kent Osborne C; van de Vijver MJ; Foekens JA; Klijn JG; Horlings HM; Nuyten D; Wang Y; Zhang Y; Chamness GC; Hilsenbeck SG; Lee AV; Schiff R
Breast Cancer Res Treat; 2009 Mar; 114(2):287-99. PubMed ID: 18425577
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS;
Ann Oncol; 2015 Jan; 26(1):81-88. PubMed ID: 25361981
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
12. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
13. TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
Zhang LY; Zhang YQ; Zeng YZ; Zhu JL; Chen H; Wei XL; Liu LJ
Breast Cancer Res Treat; 2020 Jul; 182(1):21-33. PubMed ID: 32415497
[TBL] [Abstract][Full Text] [Related]
14. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
Breast Cancer Res Treat; 2013 Jan; 137(2):397-406. PubMed ID: 23242584
[TBL] [Abstract][Full Text] [Related]
15. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
16. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
17. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
18. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
Soosanabadi M; Ghahfarokhi AM; Pourghazi F; Ehtesham N; Mirfakhraie R; Atanesyan L; Keyhani E; Behjati F
Mol Biol Rep; 2022 Sep; 49(9):8547-8553. PubMed ID: 35763181
[TBL] [Abstract][Full Text] [Related]
20. Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.
Teschendorff AE; Li L; Yang Z
Genome Biol; 2015 Apr; 16(1):61. PubMed ID: 25886003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
